1. Thank You This PowerPoint document contains the images that you requested. Copyright Notice All Online Service materials, including, without limitation, text, pictures, graphics and other files and the selection and arrangement thereof are copyrighted materials of Ovid or its licensors, all rights reserved. Except for the Authorized Use specified above, you may not copy, modify or distribute any of the Online Service materials. You may not "mirror" any material contained on this Online Service on any other server. Any unauthorized use of any material contained on this Online Service may violate copyright laws, trademark laws, the laws of privacy and publicity and communications regulations and statutes.

2. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 2 Supplementary <LINK BD >figure 1 Supplement to: Mepolizumab and exacerbations of refractory eosinophilic asthma. Haldar, P; Brightling, C; Hargadon, B New England Journal of Medicine. 360(10), March 5, 2009. Supplementary <LINK BD >figure 1 : Overview of study design</LINK>

3. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 3 Supplementary <LINK BD >Table 1 Supplement to: Mepolizumab and exacerbations of refractory eosinophilic asthma. Haldar, P; Brightling, C; Hargadon, B New England Journal of Medicine. 360(10), March 5, 2009. Supplementary <LINK BD >Table 1 : Overview and comparison of changes in secondary outcomes after treatment with mepolizumab or placebo</LINK>

4. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 4 Supplementary <LINK BD >Table 1 Supplement to: Mepolizumab and exacerbations of refractory eosinophilic asthma. Haldar, P; Brightling, C; Hargadon, B New England Journal of Medicine. 360(10), March 5, 2009. Supplementary <LINK BD >Table 1 : (continued)</LINK>

5. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 5 Supplementary <LINK BD >Table 1 Supplement to: Mepolizumab and exacerbations of refractory eosinophilic asthma. Haldar, P; Brightling, C; Hargadon, B New England Journal of Medicine. 360(10), March 5, 2009. Supplementary <LINK BD >Table 1 : (continued)</LINK>

6. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 6 Supplementary <LINK BD >Table 2 Supplement to: Mepolizumab and exacerbations of refractory eosinophilic asthma. Haldar, P; Brightling, C; Hargadon, B New England Journal of Medicine. 360(10), March 5, 2009. Supplementary <LINK BD >Table 2 : Overview of changes in measures of corticosteroid response with 2- weeks prednisolone before and after 12 months treatment with mepolizumab or placebo.</LINK>

7. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 7 Supplementary <LINK BD >Table 2 Supplement to: Mepolizumab and exacerbations of refractory eosinophilic asthma. Haldar, P; Brightling, C; Hargadon, B New England Journal of Medicine. 360(10), March 5, 2009. Supplementary <LINK BD >Table 2 : (continued)</LINK>

8. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 8 Supplementary <LINK BD >figure 2 Supplement to: Mepolizumab and exacerbations of refractory eosinophilic asthma. Haldar, P; Brightling, C; Hargadon, B New England Journal of Medicine. 360(10), March 5, 2009. Supplementary <LINK BD >figure 2 : Eosinophil counts from airway and tissue compartments at bronchoscopy before and after 12 months therapy with mepolizumab or placebo</LINK>

9. Copyright © 2009 Massachusetts Medical Society. All rights reserved. Published by Massachusetts Medical Society. 9 Supplementary <LINK BD >figure 3 Supplement to: Mepolizumab and exacerbations of refractory eosinophilic asthma. Haldar, P; Brightling, C; Hargadon, B New England Journal of Medicine. 360(10), March 5, 2009. Supplementary <LINK BD >figure 3 : Mean change in CT measured wall area (WA) and total area (TA), corrected for body surface area (BSA) after 12 months therapy with mepolizumab or placebo</LINK>